Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Canvuparatide · MBX 2109, PPL 2717

Other · developed by MBX Biosciences

Phase 3 Most advanced trial
MBX Developer
2 Registered trials

What is Canvuparatide?

Canvuparatide (MBX 2109, PPL 2717) is an agent studied in hypoparathyroidism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MBX 2109, PPL 2717
Drug type
Other
Therapy area
Endocrine
Developer
MBX Biosciences (MBX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
7YT49ZX2QZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07699471 Phase 3 Hypoparathyroidism Recruiting MBX
NCT06465108 Phase 2 Hypoparathyroidism Completed MBX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypoparathyroidism

More from MBX Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MBX page.

Follow MBX, the company behind Canvuparatide

See MBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MBX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.